Entrada Therapeutics (TRDA) Profit After Tax (2020 - 2026)
Entrada Therapeutics' (TRDA) quarterly Profit After Tax came in at -$406000.0 in Q1 2026, up 97.66% year-on-year from -$205403.4 in Q1 2025, and up 99.72% quarter-over-quarter from -$143.7 million in Q4 2025.
Entrada Therapeutics (TRDA) Profit After Tax (2020 - 2026) Analysis & Trends
Entrada Therapeutics' Profit After Tax history runs 7 years deep, the most recent figure standing at -$406000.0 for Q1 2026.
- On a quarterly basis, Profit After Tax rose 97.66% year-over-year to -$406000.0 in Q1 2026; TTM through Mar 2026 was -$143.9 million, a 798.79% decrease from a year earlier, with the FY2025 full-year figure at -$143.1 million, down 318.78% from the prior year.
- Profit After Tax rose to -$406000.0 in Q1 2026 per TRDA's latest filing, from -$143.7 million in the prior quarter.
- Across five years, Profit After Tax topped out at $67.9 million in Q4 2022 and bottomed at -$143.7 million in Q4 2025.
- The 5-year median for Profit After Tax is -$441000.0 (2024), against an average of -$12.1 million.
- Across the five-year window, Profit After Tax soared 468.02% in 2022 and plunged 123995.69% in 2025, its largest moves.
- Year by year, Profit After Tax stood at $67.9 million in 2022, then tumbled by 116.35% to -$11.1 million in 2023, then jumped by 101.04% to $116000.0 in 2024, then plunged by 123995.69% to -$143.7 million in 2025, then soared by 99.72% to -$406000.0 in 2026.
- Per Business Quant, the three latest TRDA Profit After Tax figures stand at -$406000.0 (Q1 2026), -$143.7 million (Q4 2025), and $221000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Entrada Therapeutics | 253.11 Mn | 253.11 Mn | - | -406,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -406,000.00 |
| Dec 31, 2025 | -143.72 Mn |
| Sep 30, 2025 | 221,000.00 |
| Jun 30, 2025 | -37,000.00 |
| Mar 31, 2025 | -17.35 Mn |
| Dec 31, 2024 | 116,000.00 |
| Sep 30, 2024 | 1.30 Mn |
| Jun 30, 2024 | -83,000.00 |
| Mar 31, 2024 | -441,000.00 |
| Dec 31, 2023 | -11.11 Mn |
| Sep 30, 2023 | 509,000.00 |
| Jun 30, 2023 | -25.93 Mn |
| Mar 31, 2023 | -6.67 Mn |
| Dec 31, 2022 | 67.93 Mn |
| Sep 30, 2022 | -25.62 Mn |
| Jun 30, 2022 | -23.18 Mn |
| Mar 31, 2022 | -21.67 Mn |
| Dec 31, 2021 | -18.46 Mn |
| Jun 30, 2021 | -9.90 Mn |
| Mar 31, 2021 | -8.38 Mn |